EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Monocyte Monolayer Assay as a Tool in the Early Assessment of the Severity of the Alloantibodies in Patients with Hemolytic Disease of the Fetus and Newborn

Diego Santoro, Marcelo Ielpi, Guillermo Grottola, Veronica Valiente, Carla Gamboa, Dalma Valencia, Cesar Meller, Horacio Aiello, Lucas Otaño, Pablo Camino, Leandro Burgos Pratx

Transfusion Medicine and Hemotherapy · 09.03.2026 · 1-9

DOI: 10.1159/000551424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 09.03.2026. Verfasst von Diego Santoro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Transfusional, Hospital Italiano, Buenos Aires, Argentina. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hemolytic disease of the fetus and newborn (HDFN), caused by the transplacental passage of maternal alloantibodies, can lead to progressive fetal organ failure and death from hydrops fetalis. Because serological tests often have limitations in predicting the clinical severity of these antibodies, in vitro assays have become promising tools, allowing the evaluation of the IgG-mediated extravascular hemolysis mechanism via macrophage Fc receptors. We aim to evaluate the monocyte monolayer assay (MMA), considered the most clinically validated tool for predicting in vivo survival in incompatible transfusion situations, as an early predictor of the severity of HDFN in sensitized pregnant women.

Methods

A retrospective cohort study was conducted in sensitized pregnant women at the Hospital Italiano in Buenos Aires. The MMA was performed on all patients, dividing reactivity into four groups, G1: MMA >20%, G2: MMA between 10 and 20%, G3: MMA between 5 and 10%, and G4: MMA 20% had a significantly higher rate of serious complications, including a 100% need for intrauterine transfusion (IUT). This group also experienced six fetal deaths. In contrast, the 29 patients with an MMA index

Schlagwörter

Stichwörter der Autor:innen

Hemolytic disease of the fetus and newbornIntrauterine transfusionMonocyte monolayer assay

Autor:innen und Institutionen

  • Servicio de Medicina Transfusional, Hospital Italiano, Buenos Aires, Argentina.
  • Servicio de Obstetricia, Hospital Italiano, Buenos Aires, Argentina.

Zitieren

APA

Santoro, D., Ielpi, M., Grottola, G., Valiente, V., Gamboa, C., Valencia, D., Meller, C., Aiello, H., Otaño, L., Camino, P., & Burgos Pratx, L. (2026). Monocyte Monolayer Assay as a Tool in the Early Assessment of the Severity of the Alloantibodies in Patients with Hemolytic Disease of the Fetus and Newborn. Transfusion Medicine and Hemotherapy, 1-9. https://doi.org/10.1159/000551424

Vancouver

Santoro D, Ielpi M, Grottola G, Valiente V, Gamboa C, Valencia D, et al. Monocyte Monolayer Assay as a Tool in the Early Assessment of the Severity of the Alloantibodies in Patients with Hemolytic Disease of the Fetus and Newborn. Transfusion Medicine and Hemotherapy. 2026:1-9. doi:10.1159/000551424

BibTeX
@article{Santoro2026,
  author = {Santoro, Diego and Ielpi, Marcelo and Grottola, Guillermo and Valiente, Veronica and Gamboa, Carla and Valencia, Dalma and Meller, Cesar and Aiello, Horacio and Otaño, Lucas and Camino, Pablo and Burgos Pratx, Leandro},
  title = {Monocyte Monolayer Assay as a Tool in the Early Assessment of the Severity of the Alloantibodies in Patients with Hemolytic Disease of the Fetus and Newborn},
  journal = {Transfusion Medicine and Hemotherapy},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000551424}
}
Kostenlos starten →